Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Allogene Therapeuticsallogene.com · Low evidenceAllogene Therapeutics is developing AlloCAR T products, which are allogeneic CAR T cell therapies designed to treat blood cancers, solid tumors, and autoimmune diseases. Their platform aims to provide an off-the-shelf, scalable treatment with the potential to treat over 100 patients from a single manufacturing run.
Parse Score